Predicting Prognosis and Tamoxifen Response in Breast Cancer. With a special focus on contralateral breast cancer.

摘要: One of the great challenges in breast cancer treatment today is to customize adjuvant each patient’s individual needs. To do this it necessary learn more about prognostic and predictive factors that determine risk relapse response a certain mode treatment. This thesis describes studies on effect amplified 1 (AIB1), coactivator oestrogen receptor, prognosis tamoxifen through controlled trial premenopausal patients randomized or control group. AIB1 was found be negative factor, although with high responded very well tamoxifen. The findings were validated two independent cohorts, one consisting not receiving tamoxifen, other pre- postmenopausal tamoxifen. It has recently been suggested modified by paired box 2 gene product (PAX2). PAX2 transcription factor important during embryogenesis, may also play role carcinogenesis. first time investigated well-defined cohorts affect its own, modify AIB1. The second part focuses contralateral (CBC). Within their lifetime, previous have 2-20% developing tumour breast. From control, without 12% developed CBC within median follow-up period 14 years. even higher youngest women (<40 years), which 20% CBC. Treatment reduced 50% all patients, 90% women. Since still rather rare event, are often small based only register data. Detailed patient, information collected for large cohort (>700) Southern Healthcare Region Sweden. these data short interval between tumours associated poorer prognosis, especially young patients. could indicate some CBCs fact metastases tumour, would thus require different It develop soon after resistance aggressive phenotype. Finally, who noticed symptoms themselves had than diagnosed mammography clinical examination programme. difference relation detection remained when ≥10 years, indicating long valuable.